Prashant R Murumkar

List of Publications by Citations

Source: https://exaly.com/author-pdf/1011321/prashant-r-murumkar-publications-by-citations.pdf
Version: 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

52 papers	1,051 citations	20 h-index	31 g-index
58 ext. papers	1,225 ext. citations	4 avg, IF	4.37 L-index

#	Paper	IF	Citations
52	Current perspective of TACE inhibitors: a review. *Bioorganic and Medicinal Chemistry*, **2009**, 17, 444-59	3.4	102
51	Angiotensin II receptor type 1 (AT1) selective nonpeptidic antagonists--a perspective. *Bioorganic and Medicinal Chemistry*, **2010**, 18, 8418-56	3.4	81
50	Benzylpiperidine-Linked Diarylthiazoles as Potential Anti-Alzheimer's Agents: Synthesis and Biological Evaluation. *Journal of Medicinal Chemistry*, **2016**, 59, 5823-46	8.3	60
49	Unequivocal role of pyrazine ring in medicinally important compounds: a review. *Mini-Reviews in Medicinal Chemistry*, **2013**, 13, 1607-25	3.2	57
48	Overview of the Development of DprE1 Inhibitors for Combating the Menace of Tuberculosis. *Journal of Medicinal Chemistry*, **2018**, 61, 8563-8593	8.3	51
47	Prospective therapeutic agents for obesity: molecular modification approaches of centrally and peripherally acting selective cannabinoid 1 receptor antagonists. *European Journal of Medicinal Chemistry*, **2014**, 79, 298-339	6.8	47
46	Developing steroidal aromatase inhibitors-an effective armament to win the battle against breast cancer. *European Journal of Medicinal Chemistry*, **2015**, 105, 1-38	6.8	44
45	Novel TACE inhibitors in drug discovery: a review of patented compounds. *Expert Opinion on Therapeutic Patents*, **2010**, 20, 31-57	6.8	44
44	Prodrug designing of NSAIDs. *Mini-Reviews in Medicinal Chemistry*, **2009**, 9, 124-39	3.2	44
43	Medicinal Chemistry Perspective of Fused Isoxazole Derivatives. *Current Topics in Medicinal Chemistry*, **2016**, 16, 2863-2883	3	44
42	Development of predictive pharmacophore model for in silico screening, and 3D QSAR CoMFA and CoMSIA studies for lead optimization, for designing of potent tumor necrosis factor alpha converting enzyme inhibitors. *Journal of Computer-Aided Molecular Design*, **2010**, 24, 143-56	4.2	35
41	3D-quantitative structure-activity relationship studies on benzothiadiazepine hydroxamates as inhibitors of tumor necrosis factor-alpha converting enzyme. *Chemical Biology and Drug Design*, **2008**, 71, 363-73	2.9	32
40	Contemporary developments in the discovery of selective factor Xa inhibitors: A review. *European Journal of Medicinal Chemistry*, **2016**, 121, 671-698	6.8	28
39	Dihydropyrimidinone-isatin hybrids as novel non-nucleoside HIV-1 reverse transcriptase inhibitors. *Bioorganic Chemistry*, **2017**, 70, 256-266	5.1	27
38	Development of predictive 3D-QSAR CoMFA and CoMSIA models for beta-aminohydroxamic acid-derived tumor necrosis factor-alpha converting enzyme inhibitors. *Chemical Biology and Drug Design*, **2009**, 73, 97-107	2.9	27
37	Studies on novel 2-imidazolidinones and tetrahydropyrimidin-2(1H)-ones as potential TACE inhibitors: design, synthesis, molecular modeling, and preliminary biological evaluation. *Bioorganic and Medicinal Chemistry*, **2009**, 17, 3604-17	3.4	26
36	Structural investigations of acridine derivatives by CoMFA and CoMSIA reveal novel insight into their structures toward DNA G-quadruplex mediated telomerase inhibition and offer a highly predictive 3D-model for substituted acridines. *Journal of Chemical Information and Modeling*, **2009**, 49, 1298-311	6.1	25

35	A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. *Expert Opinion on Therapeutic Patents*, **2015**, 25, 1093-116	6.8	22
34	Development of highly predictive 3D-QSAR CoMSIA models for anthraquinone and acridone derivatives as telomerase inhibitors targeting G-quadruplex DNA telomere. *Journal of Molecular Graphics and Modelling*, **2010**, 29, 229-39	2.8	22
33	Novel methods and strategies in the discovery of TACE inhibitors. *Expert Opinion on Drug Discovery*, **2013**, 8, 157-81	6.2	21
32	Novel Multitarget Directed Triazinoindole Derivatives as Anti-Alzheimer Agents. *ACS Chemical Neuroscience*, **2019**, 10, 3635-3661	5.7	20
31	Determination of structural requirements of influenza neuraminidase type A inhibitors and binding interaction analysis with the active site of A/H1N1 by 3D-QSAR CoMFA and CoMSIA modeling. *MedChemComm*, **2011**, 2, 710	5	15
30	Design of selective TACE inhibitors using molecular docking studies: Synthesis and preliminary evaluation of anti-inflammatory and TACE inhibitory activity. *SAR and QSAR in Environmental Research*, **2015**, 26, 905-23	3.5	14
29	Virtual screening-based identification of lead molecules as selective TACE inhibitors. *Medicinal Chemistry Research*, **2015**, 24, 226-244	2.2	13
28	Synthesis and biological evaluation of some novel pyrido[1,2-a]pyrimidin-4-ones as antimalarial agents. *European Journal of Medicinal Chemistry*, **2014**, 79, 422-35	6.8	13
27	Synthesis, preliminary biological evaluation and molecular modeling of some new heterocyclic inhibitors of TACE. *European Journal of Medicinal Chemistry*, **2011**, 46, 5549-55	6.8	12
26	Three-dimensional quantitative structure–activity relationship CoMFA/CoMSIA on pyrrolidine-based tartrate diamides as TACE inhibitors. *Medicinal Chemistry Research*, **2013**, 22, 4192-4201	2.2	10
25	New pyrazolyl-dibenzo[b,e][1,4]diazepinones: room temperature one-pot synthesis and biological evaluation. *Molecular Diversity*, **2020**, 24, 355-377	3.1	9
24	Vicinal diaryl azole-based urea derivatives as potential cholesterol lowering agents acting through inhibition of SOAT enzymes. *European Journal of Medicinal Chemistry*, **2017**, 130, 107-123	6.8	8
23	Exploring structural requirements for peripherally acting 1,5-diaryl pyrazole-containing cannabinoid 1 receptor antagonists for the treatment of obesity. *Molecular Diversity*, **2015**, 19, 871-93	3.1	8
22	Advances in the Development of Novel Factor Xa Inhibitors: A Patent Review. *Mini-Reviews in Medicinal Chemistry*, **2018**, 18, 1332-1353	3.2	8
21	New role of phenothiazine derivatives as peripherally acting CB1 receptor antagonizing anti-obesity agents. *Scientific Reports*, **2018**, 8, 1650	4.9	7
20	Development of a credible 3D-QSAR CoMSIA model and docking studies for a series of triazoles and tetrazoles containing 11β-HSD1 inhibitors. *SAR and QSAR in Environmental Research*, **2016**, 27, 265-92	3.5	7
19	Recent developments and strategies for the discovery of TACE inhibitors. *Expert Opinion on Drug Discovery*, **2020**, 15, 779-801	6.2	7
18	A catalyst- and solvent-free multicomponent synthesis and docking study of some new antiproliferative N5-allyl-quinolylpyrido[2,3-b][1,4]benzodiazepinone precursors. *New Journal of Chemistry*, **2016**, 40, 4931-4939	3.6	6

17	Discovery of anti-malarial agents through application of in silico studies. *Combinatorial Chemistry and High Throughput Screening*, **2015**, 18, 151-87	1.3	6
16	Gemini Amphiphile-Based Lipoplexes for Efficient Gene Delivery: Synthesis, Formulation Development, Characterization, Gene Transfection, and Biodistribution Studies. *ACS Omega*, **2018**, 3, 11802-11816	3.9	6
15	Identifying the structural features and diversifying the chemical domain of peripherally acting CB1 receptor antagonists using molecular modeling techniques. *RSC Advances*, **2016**, 6, 1466-1483	3.7	5
14	One-pot synthesis, biological evaluation, and docking study of new chromeno-annulated thiopyrano[2,3-c]pyrazoles. *Molecular Diversity*, **2016**, 20, 639-57	3.1	5
13	Drug-fortified liposomes as carriers for sustained release of NSAIDs: The concept and its validation in the animal model for the treatment of arthritis. *European Journal of Pharmaceutical Sciences*, **2018**, 125, 11-22	5.1	5
12	Advances in studies on collagenase inhibitors. *Exs*, **2012**, 103, 83-135		4
11	Synthesis and investigation of anti-inflammatory activity of novel nitric oxide donating hybrid drugs. *Medicinal Chemistry Research*, **2013**, 22, 3510-3517	2.2	3
10	Vicinal Diaryl Oxadiazoles, Oxazoles, and Isoxazoles **2018**, 277-303		2
9	Vicinal Diaryl Triazoles and Tetrazoles **2018**, 191-219		2
8	3-Substituted 1-methyl-3-benzazepin-2-ones as 5-HT2C receptor agonists. *RSC Advances*, **2015**, 5, 91908-91921	3.7	1
7	Exploration of 6,7-dimethoxyquinazoline derivatives as dual acting □- and AT1-receptor antagonists: synthesis, evaluation, pharmacophore & 3D-QSAR modeling and receptor docking studies. *RSC Advances*, **2016**, 6, 30661-30682	3.7	1
6	Development of Steroidal Aromatase Inhibitors as Potential Anti-breast Cancer Agents. *Current Enzyme Inhibition*, **2020**, 16, 45-62	0.5	1
5	Design and synthesis of novel N-[3-(benzimidazol-2-ylamino)phenyl]amine and N-[3-(benzoxazol-2-ylamino)phenyl]amine derivatives as potential anticancer agents. *Molecular Diversity*, **2021**, 1	3.1	1
4	Computational Modelling of Kinase Inhibitors as Anti-Alzheimer Agents. *Neuromethods*, **2018**, 347-417	0.4	1
3	Swertisin, a novel SGLT2 inhibitor, with improved glucose homeostasis for effective diabetes therapy. *Archives of Biochemistry and Biophysics*, **2021**, 710, 108995	4.1	1
2	Further Studies on Cationic Gemini Amphiphiles as Carriers for Gene Delivery-The Effect of Linkers in the Structure and Other Factors Affecting the Transfection Efficacy of These Amphiphiles.. *ACS Omega*, **2021**, 6, 33370-33388	3.9	0
1	Design, synthesis and evaluation of 4,7-disubstituted 8-methoxyquinazoline derivatives as potential cytotoxic agents targeting □catenin/TCF4 signaling pathway.. *Translational Oncology*, **2022**, 19, 101395	4.9	